CD274 and cancer: Since these treatments could improve T cell effector functions against cancer cells due to the inhibitory effects of 10_12 mAb in the PD-1/PD-L1 interaction [59] between tumor cells and T cells, we also verified the ability of the indicated compounds to induce the secretion of cytokines by lymphocytes involved in immunological surveillance.